PlainRecalls
FDA Drug Low Class III Terminated

Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 54092-606-07) and b) 4 pouches x 5 single-use containers (NDC 54092-606-04), Rx Only, Manufactured for: Shire US Inc., 300 Shire Way, Lexington, MA 02421.

Reported: June 15, 2022 Initiated: May 10, 2022 #D-0985-2022

Product Description

Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 54092-606-07) and b) 4 pouches x 5 single-use containers (NDC 54092-606-04), Rx Only, Manufactured for: Shire US Inc., 300 Shire Way, Lexington, MA 02421.

Reason for Recall

Failed Impurities/Degradation Specifications.

Details

Units Affected
279,179 vials
Distribution
Nationwide within the United States
Location
East Hanover, NJ

Frequently Asked Questions

What product was recalled?
Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 54092-606-07) and b) 4 pouches x 5 single-use containers (NDC 54092-606-04), Rx Only, Manufactured for: Shire US Inc., 300 Shire Way, Lexington, MA 02421.. Recalled by Novartis Pharmaceuticals Corporation. Units affected: 279,179 vials.
Why was this product recalled?
Failed Impurities/Degradation Specifications.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 15, 2022. Severity: Low. Recall number: D-0985-2022.